Pharmaceutical company Zydus Cadila has sought approval to use its new drug 'Candidate' ZYIL1 as a test in the treatment of severely affected patients of COVID-19.
The company gave this information in a notice sent to the stock markets. The company said, "After its initiative of vaccines and therapy in the fight against COVID-19, it is now focusing on cutting-edge research for targeted treatment."
Zydus Cadila said that ZYIL 1 will cater to a variety of inflammatory diseases and treatment needs of the current COVID-19 epidemic and chronic diseases. The company said that it has applied IND after completing all the studies related to IND.